Abstract
Background: Current National Cholesterol Education Program (NCEP) guidelines recognize low‐density lipoprotein cholesterol (LDL‐C) below 100 mg/dl as an optimal level. Evidence supporting this is scant. Both LDL‐C and C reactive protein (CRP) are known correlates of atherosclerosis progression.
Hypothesis: We examined the effect of final LDL‐C and CRP obtained with statin therapy on carotid intima‐media thickness (CIMT), a valid surrogate for clinical benefit of lipid‐lowering therapies.
Methods: In a randomized, single‐center trial, 161 patients were assigned to statin therapy of different potencies (pravastatin 40 mg, n = 82; atorvastatin 80 mg, n=79). The effects on CIMT were assessed in relationship to LDL‐C and CRP levels obtained after 12 months of therapy.
Results: Changes in CIMT were directly related to the final LDL‐C level obtained on statin therapy after 12 months (R = 0.219, p = 0.015). Carotid intima‐media thickness regression was seen in 61% of the subjects in the lowest quartile of final LDL‐C (≤ 70 mg/dl) versus 29% of the subjects with the highest quartile of final LDL‐C (≥ 114 mg/dl, p = 0.008). No threshold value was seen, with more favorable effects on absolute change in CIMT with lower values of LDL‐C (decrease in CIMT of 0.06 ±0.17 mm in the lowest quartile compared with an increase of 0.06 ± 0.09 in the highest quartile of LDL‐C, p = 0.008). On‐treatment LDL and CRP concentrations both below the group median values were associated with the greatest likelihood of CIMT regression.
Conclusions: Regression of carotid atherosclerosis is directly related to the absolute LDL‐C level on statin therapy. The greatest regression was obtained with an LDL‐C <70 mg/dl, supporting marked LDL‐C reduction to levels below current NCEP guidelines.
Full Text
The Full Text of this article is available as a PDF (114.9 KB).
References
- 1. Furberg CD, Adams HPJ, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679–1687 [DOI] [PubMed] [Google Scholar]
- 2. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G: Low‐dose metoprolol CR/XL and fluvastatin slow progression of carotid intima‐media thickness: Main results from the Beta‐Blocker Cholesterol‐Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721–1726 [DOI] [PubMed] [Google Scholar]
- 3. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC‐II). Am J Cardiol 1995; 75: 455–459 [DOI] [PubMed] [Google Scholar]
- 4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2497 [DOI] [PubMed] [Google Scholar]
- 5. Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446–1452 [DOI] [PubMed] [Google Scholar]
- 6. Markwood TT, Kent SM, Coyle LC, Flaherty PJ, O'Malley PG, Taylor AJ: Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)—a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima‐media thickness. Am Heart J 2001; 141: 342–347 [DOI] [PubMed] [Google Scholar]
- 7. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A: Relationship between lipid levels and clinical outcomes in the Long‐term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: To what extent is the reduction in coronary events with pravastatin explained by on‐study lipid levels? Circulation 2002; 105: 1162–1169 [DOI] [PubMed] [Google Scholar]
- 8. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double‐blind trial. Lancet 2001; 357: 577–581 [DOI] [PubMed] [Google Scholar]
- 9. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama S, Yamanishi H, Matsumoto M, Hori M: C‐reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001; 104: 63–67 [DOI] [PubMed] [Google Scholar]
- 10. Zwaka TP, Hombach V, Torzewski J: C‐reactive protein‐mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001; 103: 1194–1197 [DOI] [PubMed] [Google Scholar]
- 11. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979 [DOI] [PubMed] [Google Scholar]